These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39036962)

  • 1. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma.
    Mohan A; Quingalahua E; Gunchick V; Paul S; Kumar-Sinha C; Crysler O; Zalupski MM; Sahai V
    Oncologist; 2024 Aug; 29(8):725-730. PubMed ID: 39036962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
    Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
    Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
    Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
    Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
    Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
    Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum Sensitivity in
    Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
    Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
    Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
    Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of
    Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
    Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
    [No Abstract]   [Full Text] [Related]  

  • 12. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
    Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
    Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
    Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
    Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Crispo F; Pietrafesa M; Condelli V; Maddalena F; Bruno G; Piscazzi A; Sgambato A; Esposito F; Landriscina M
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
    J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
    Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
    Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
    Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
    JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
    Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
    JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.